These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 3063494)

  • 21. [Evaluation of the in vitro activity of enoxacin on bacterial strains recently isolated in a hospital milieu].
    Lembo M; Nani E; Covelli I; Amato G; Lavitola A
    G Batteriol Virol Immunol; 1985; 78(7-12):205-16. PubMed ID: 3870425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incomplete cross-resistance of nalidixic and pipemidic acid-resistant variants of Serratia marcescens against ciprofloxacin, enoxacin, and norfloxacin.
    Traub WH
    Chemotherapy; 1985; 31(1):34-9. PubMed ID: 3156026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cefixime. A review of its antibacterial activity. Pharmacokinetic properties and therapeutic potential.
    Brogden RN; Campoli-Richards DM
    Drugs; 1989 Oct; 38(4):524-50. PubMed ID: 2684593
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Urinary tract infections: risk factors and therapeutic trends].
    Margariti PA; Astorri AL; Mastromarino C
    Recenti Prog Med; 1997 Feb; 88(2):65-8. PubMed ID: 9148368
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro activity of lomefloxacin, a new difluorinated quinolone, against urinary bacterial isolates: comparison with enoxacin and ofloxacin.
    Azadian BS; Talboys CA; Roberts AP
    J Chemother; 1989 Jul; 1(4 Suppl):176-7. PubMed ID: 16312357
    [No Abstract]   [Full Text] [Related]  

  • 26. Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections.
    Patel SS; Balfour JA; Bryson HM
    Drugs; 1997 Apr; 53(4):637-56. PubMed ID: 9098664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of the fluoroquinolones.
    Guay DR
    Pharmacotherapy; 1992; 12(6 Pt 2):71S-85S. PubMed ID: 1480503
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fleroxacin overview.
    Naber KG
    Chemotherapy; 1996 Mar; 42 Suppl 1():1-9. PubMed ID: 8861529
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The response of Streptococcus faecalis to ciprofloxacin, norfloxacin and enoxacin.
    Muranaka K; Greenwood D
    J Antimicrob Chemother; 1988 May; 21(5):545-54. PubMed ID: 3134318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enoxacin for the treatment of urinary tract infection.
    Bailey RR; Peddie BA
    N Z Med J; 1985 Apr; 98(777):286-8. PubMed ID: 3857511
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tissue penetration and clinical efficacy of enoxacin in respiratory tract infections.
    Wood MJ
    Clin Pharmacokinet; 1989; 16 Suppl 1():38-45. PubMed ID: 2653694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Short-term therapy of acute uncomplicated cystitis.
    Naber KG
    Curr Opin Urol; 1999 Jan; 9(1):57-64. PubMed ID: 10726073
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levofloxacin and sparfloxacin: new quinolone antibiotics.
    Martin SJ; Meyer JM; Chuck SK; Jung R; Messick CR; Pendland SL
    Ann Pharmacother; 1998 Mar; 32(3):320-36. PubMed ID: 9533064
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quinolone penetration into canine vaginal and urethral secretions.
    Gasser TC; Graversen PH; Larsen EH; Dørflinger T
    Scand J Urol Nephrol Suppl; 1987; 104():101-5. PubMed ID: 3481457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravenous enoxacin for the treatment of acute pyelonephritis: pharmacokinetic and clinical study.
    Bailey RR; Walker RJ; Lynn KL; Donaldson IM; Peddie BA; Dobbs BR
    Br J Clin Pharmacol; 1988 Feb; 25(2):223-8. PubMed ID: 3162809
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enoxacin treatment of urinary tract infections in elderly patients.
    Huttunen M; Kunnas K; Saloranta P
    J Antimicrob Chemother; 1988 Feb; 21 Suppl B():105-11. PubMed ID: 3162900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections.
    Onrust SV; Lamb HM; Balfour JA
    Drugs; 1998 Nov; 56(5):895-928. PubMed ID: 9829160
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The effectiveness of enoxacin for the treatment of complicated urinary tract infection].
    Germinario C; Quarto M; Viggiani N; Schena FP
    Riv Eur Sci Med Farmacol; 1992; 14(5):347-51. PubMed ID: 1308966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule.
    Wise R; Griggs D; Andrews JM
    Rev Infect Dis; 1988; 10 Suppl 1():S83-9. PubMed ID: 3162327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Comparison of fluoroquinolones (norfloxacin, enoxacin, ofloxacin) in the therapy of lower urinary tract infections].
    Tizzani A; Casetta G; Cavallini A; Piana P
    Minerva Urol Nefrol; 1990; 42(2):81-4. PubMed ID: 2392745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.